» Articles » PMID: 8065309

Effects of C-myc Expression on Cell Cycle Progression

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1994 Sep 1
PMID 8065309
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

We used targeted homologous recombination to disrupt one c-myc gene copy in a diploid fibroblast cell line and found that a twofold reduction in Myc expression resulted in lower exponential growth rates and a lengthening of the G0-to-S-phase transition (M. Shichiri, K. D. Hanson and J. M. Sedivy, Cell Growth Differ. 4:93-104, 1993). Myc is a transcription factor, and the number of target genes whose regulation could result in differential growth rates may be very large. We have approached this problem by examining effects of reduced c-myc expression in three broad areas: (i) secretion of growth factors, (ii) expression of growth factor receptors, and (iii) intracellular signal transduction between Myc and components of the intrinsic cell cycle clock. We have found no evidence that differential medium conditioning can account for the growth phenotypes. Likewise, the expression of receptors for platelet-derived growth factor, epidermal growth factor, basic fibroblast growth factor, and insulin-like growth factor I was the same in diploid and heterozygous cells (platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor are the sole growth factors required by these cells for growth in serum-free medium). In contrast, expression of cyclin E, cyclin A, and Rb phosphorylation were delayed when quiescent c-myc heterozygous cells were stimulated to enter the cell cycle. Expression of cyclin D1, cyclin D3, and Cdk2 was not affected. The timing of cyclin E induction was the earliest observable effect of reduced Myc expression. Our data indicate that Myc contributes to regulation of proliferation by a cell-autonomous mechanism that involves the modulation of cyclin E expression and, consequently, progression through the restriction point of the cell cycle.

Citing Articles

c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a.

Dong C, Sun Y, Xu X, Li H, Song X, Wei W Breast Cancer. 2025; .

PMID: 40029493 DOI: 10.1007/s12282-025-01683-w.


MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.

Chan K, Zhang S, Li G, Xu Y, Cui L, Wang Y Aging Dis. 2023; 15(2):640-697.

PMID: 37450923 PMC: 10917530. DOI: 10.14336/AD.2023.0520.


Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression.

Tang X, Cromwell C, Liu R, Godbout R, Hubbard B, McMullen T Theranostics. 2022; 12(13):5675-5690.

PMID: 35966578 PMC: 9373824. DOI: 10.7150/thno.66230.


Defective bone repletion in aged Balb/cBy mice was caused by impaired osteoblastic differentiation.

Sheng M, Lau K, Rundle C, Alsunna A, Wilson S, Baylink D J Bone Miner Metab. 2022; 40(6):900-913.

PMID: 35947191 PMC: 9722502. DOI: 10.1007/s00774-022-01361-3.


ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells.

Sun Y, Sha B, Huang W, Li M, Zhao S, Zhang Y Apoptosis. 2022; 27(7-8):545-560.

PMID: 35654870 DOI: 10.1007/s10495-022-01736-x.


References
1.
Blackwell T, Kretzner L, Blackwood E, Eisenman R, Weintraub H . Sequence-specific DNA binding by the c-Myc protein. Science. 1990; 250(4984):1149-51. DOI: 10.1126/science.2251503. View

2.
Luscher B, Eisenman R . New light on Myc and Myb. Part I. Myc. Genes Dev. 1990; 4(12A):2025-35. DOI: 10.1101/gad.4.12a.2025. View

3.
Prendergast G, Ziff E . Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science. 1991; 251(4990):186-9. DOI: 10.1126/science.1987636. View

4.
Bishop J . Molecular themes in oncogenesis. Cell. 1991; 64(2):235-48. DOI: 10.1016/0092-8674(91)90636-d. View

5.
Hunter T . Cooperation between oncogenes. Cell. 1991; 64(2):249-70. DOI: 10.1016/0092-8674(91)90637-e. View